Discussion
RAG-17, an experimental RNA-targeting therapy designed to treat amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, was generally well tolerated and substantially lowered two disease-related biomarkers in a first-in-human Phase 1 trial involving six people. The investigational therapy also showed promise in animal studies, delaying disease onset…